ZYBERNO
Stock Report
Updated Sep 1, 2026

APIMEDS PHARMACEUTICALS US, INC. (APUS)

Healthcare • NYSE

$3.88

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
8.0/100
POOR BUSINESS
APIMEDS PHARMACEUTICALS US, INC. (APUS) scores 8/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-59.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-18.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

APIMEDS PHARMACEUTICALS US, INC. (APUS) stock report — Zyberno Score 8/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.88
Market Cap:$6.65M

Valuation Multiples (2)

P/B Ratio:0.06x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$9.69M
B. Profitability Assessment

Return Metrics (5)

ROA:-52.6%
Reinvestment Rate:-0.2%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$313.63
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.51x
Quick Ratio:0.51x
Cash Ratio:0.01x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-2.77x
Times Interest Earned:-2.77

Capital Structure (4)

Working Capital:-10,394,845.00
Cash And Cash Equivalents:278,371.00
Long Term Debt:$101.87K
Net Debt:$3.05M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$27.35M

Bottom Line Performance (3)

-$58.17M
Income Before Tax:$0.00
Ebitda Ttm:-27,343,038.00

Operating Expenses (5)

Operating Expenses:22,972,597.00
R And D Expense:3,132,363.00
Sga Expense:24,507,061.00
Income Tax Expense:$0.00
Interest Expense:4,305,085.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$127.62M
Current Assets:$10.68M
Ppe Net:51,929.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:21,175,156.00
Current Liabilities:21,073,283.00
Long Term Debt:$101.87K
Short Term Debt:$3.22M

Equity & Capital (3)

Equity:$106.45M
Retained Earnings:-$65.63M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,221,643.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:105,210.00
C. Cash Flow Analysis

Operating Activities (2)

-$10.97M-$8.98M

Investment Activities (1)

Investing Cash Flow:$490.61K

Financing Activities (3)

Financing Cash Flow:$920.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:11,629,727.00
Long Term Debt Issuance:$3.00M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:5,706.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-14.27
-$14.27
Earnings Per Share Ttm:-$33.95

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$5.21

Book Value & Capital (2)

Book Value Per Share:$62.13
Cash Per Share:0.16

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.2%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):100.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:APUS
Company Name:APIMEDS PHARMACEUTICALS US, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.71M
Shares Outstanding Basic:1.71M
Shares Outstanding Diluted:1.71M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 12:17:52 UTC
Data Timestamp:2026-08-21T05:18:57.190087
Scroll to Top